Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Total pre-tax Non-GAAP adjustments by Year
Total pre-tax Non-GAAP adjustments (SBC, intangible amortization, contingent consideration & acquisition costs, $M) ($M)
Vertex Pharmaceuticals Total pre-tax Non-GAAP adjustments: $1,095M in FY2025, up 11.0% from a year earlier. That is the highest of the 8 years on record here.
Where the FY2025 figure comes from
“|| Total non-GAAP adjustments to pre-tax income | 157.1 | 179.5 | 1,094.8 | 986.2”
Source: Form 8-K (ex-991_q42025.htm, filed 2026-02-12) ↗
Reported in Form 8-K EX-99.1 Earnings Releases (GAAP to Non-GAAP Reconciliations).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total pre-tax Non-GAAP adjustments (SBC, intangible amortization, contingent consideration & acquisition costs, $M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,095 | +11.0% | Form 8-K (ex-991_q42025.htm, filed 2026-02-12) ↗ |
| FY2024 | Dec 31, 2024 | 986 | +81.6% | Form 8-K (ex-991_q42025.htm, filed 2026-02-12) ↗ |
| FY2023 | Dec 31, 2023 | 543 | -14.4% | Form 8-K (ex-991_q42024.htm, filed 2025-02-10) ↗ |
| FY2022 | Dec 31, 2022 | 635 | +46.8% | Form 8-K (ex-991_q42023.htm, filed 2024-02-05) ↗ |
| FY2021 | Dec 31, 2021 | 433 | +33.9% | Form 8-K (ex-991_q42022.htm, filed 2023-02-07) ↗ |
| FY2020 | Dec 31, 2020 | 323 | -17.3% | Form 8-K (ex-991_q42021.htm, filed 2022-01-26) ↗ |
| FY2019 | Dec 31, 2019 | 391 | -15.3% | Form 8-K (ex-991_q42020.htm, filed 2021-02-01) ↗ |
| FY2018 | Dec 31, 2018 | 462 | – | Form 8-K (ex-991q42019.htm, filed 2020-01-30) ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals Total pre-tax Non-GAAP adjustments ($M), annual FY2018–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/nongaap-pretax-adj
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.